Zachary T. Bloomgarden, MD, MACE: We have to have rational drug pricing. We have to change, in such a fashion, to have the cost of drugs in America not differ from the cost of drugs in the United Kingdom, France, Germany, China, or Japan, for that matter. We need to have an effective approach to making drugs available for everyone.
Currently, individuals who have Medicare Part D have a huge burden of paying for drugs once they reach the so-called donut hole, and that certainly needs to change. But, most importantly, we have to stop confusing the cost of the drug, in terms of buying the product, [with] the cost of the drug in terms of its likelihood of ultimately affording benefit to the individual in question.
This is an area in which I fear that we’ve erred tremendously. We allow higher-cost versus lower-cost drugs to be prescribed less frequently, even though the higher-cost drugs may truly be better. So, we have to rethink some of our concepts.
What It Takes to Improve Guideline-Based Heart Failure Care With Ty J. Gluckman, MD
August 5th 2025Explore innovative strategies to enhance heart failure treatment through guideline-directed medical therapy, remote monitoring, and artificial intelligence–driven solutions for better patient outcomes.
Listen
Semaglutide Linked to Cardiovascular Gains, but Also Higher Health Spending
August 8th 2025A real-world study found that semaglutide prescriptions were associated with improvements in weight, blood pressure, and cholesterol, but also a $80 monthly rise in health care spending outside of drug costs.
Read More
Immune Checkpoint Inhibitors More Effective vs Bevacizumab in Nonsquamous NSCLC
August 6th 2025Bevacizumab combined with chemotherapy was not as effective in advanced driver gene-negative nonsquamous non–small cell lung cancer (NSCLC) compared with immune checkpoint inhibitors plus chemotherapy.
Read More